How a new "breathalyzer" from the College of Veterinary Medicine could change the future of canine heart health.
Heart disease affects approximately 10 percent of dogs in their lifetime 1 VETMEDIN® (pimobendan) from Boehringer Ingelheim is the only medication approved to treat preclinical mitral valve disease in ...
The MarketWatch News Department was not involved in the creation of this content. -- Heart disease affects approximately 10 percent of dogs in their lifetime1 -- VETMEDIN(R) (pimobendan) from ...
Jan 19 (Reuters) - Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable tablet, as the first drug to delay congestive heart ...